ERBB2 and ductal breast carcinoma in situ: described a case with a clinical course remarkably similar to ours: a patient with HER2‐positive MPD with DCIS and dermal microinvasion experienced systemic recurrence (including carcinomatous lymphangiosis of the lung) just 18 months after mastectomy, and also achieved a complete response with taxane‐trastuzumab combination therapy [19].